Bayer secures FDA approval for hemophilia A treatment drug Jivi
In a major advancement for hemophilia A therapy, Bayer’s recombinant factor VIII (rFVIII) replacement therapy, Jivi (BAY94-9027), has received approval from the U.S. Food and Drug Administration (FDA) for routine preventative treatment in individuals aged 12 years and older. This approval marks Jivi as the third hemophilia A treatment drug from Bayer to gain FDA […]